KY-556 (N556) (Synonyms: N556) |
| Catalog No.GC31971 |
Le KY-556 (N556) est un promédicament prometteur et actif par voie orale du cromoglycate disodique (DSCG) contre les maladies allergiques.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 110816-78-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
KY-556 is a promising and orally-active pro-drug of disodium cromoglycate (DSCG) against allergic diseases.
The oral anti-allergic effect of KY-556 (N-556) is investigated. N-556 (10-100 mg/kg, p.o.) inhibits dose-dependently the 48-hr homologous passive cutaneous anaphylaxis (PCA) in rats, and the duration of action is longer than that of intravenous Disodium cromoglycate (DSCG). N-556 (20 and 100 mg/kg once a day for 20 consecutive days, p.o.) tends to inhibit the histamine release from actively sensitized rat lung fragments. N-556 (100 mg/kg, p.o.) shows the prolongation of survival time in the rat systemic anaphylaxis. N-556 (100 mg/kg, p.o.) significantly inhibits the increased airway resistance in experimental asthma in rats[1].
[1]. Nakamura S, et al. Effects of N-556 on experimental allergy models in rats. Arerugi. 1990 Dec;39(12):1621-8.
Average Rating: 5 (Based on Reviews and 11 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *